High-Dose Chemotherapy and Stem Cell Support for Breast Cancer
To date, there is no definitive evidence that high-dose chemotherapy and haematopoietic stem cell support offers a survival advantage over conventional-dose chemotherapy for metastatic or high-risk primary breast cancer. Studies of metastatic disease discussed in this review have an adequate duration of follow-up given the short natural history of metastatic breast cancer. Thus, the results of these studies are unlikely to change with a longer observation period. On the other hand, studies of high-dose chemotherapy in the treatment of high-risk primary breast cancer need longer follow-up in light of the longer natural history of this type of disease. Results of unpublished studies and longer follow-up of available studies may still demonstrate a survival advantage for high-dose chemotherapy in patients with metastatic or high-risk primary breast cancer. We continue to encourage participation in innovative clinical studies.
KeywordsBreast Cancer Metastatic Breast Cancer Induction Chemotherapy Acute Myeloid Leukaemia Autologous Bone Marrow Transplantation
No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
- 3.Berry D, Demetri G, Cirrincione C, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 101Google Scholar
- 4.Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-22. J Clin Oncol 1997; 15: 1858–69PubMedGoogle Scholar
- 22.Spitzer TR, Cirenza E, McAfee S, et al. Phase I–II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 527–42Google Scholar
- 25.ABMTR Newsletter 1998; 5: 5Google Scholar
- 27.Bezwoda WR. Randomized, controlled trial of high dose chemotherapy (HD-CNV) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18: 2aGoogle Scholar
- 29.Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: results of the French protocol PEGASE 04 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 43aGoogle Scholar
- 30.Peters WP, Jones RB, Vredenburg J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CBP) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 121Google Scholar
- 31.Madan B, Broadwater G, Rubin P, et al. Improved survival with consolidation high dose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastasis treated with induction adriamycin, 5-fluorouracil and methotrexate (AFM): a phase III prospective randomized comparative trial [abstract]. Proc Am Soc Clin Oncol 2000; 19: 48aGoogle Scholar
- 32.Daly MB, Goldstein LJ, Topolsky D, et al. Quality of life experience in women randomized to high-dose chemotherapy (HDC) and stem cell support (SCT) or standard dose chemotherapy for responding metastatic breast cancer in Philadelphia Intergroup Study (PBT-1) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 327Google Scholar
- 33.Schulman KA, Glick HA, Goldstein LJ, et al. Economic analysis of high-dose chemotherapy for women with responding metastatic breast cancer in the Philadelphia Intergroup Study (PBT-1) [abstract]. Proc Am Soc Clin Oncol 2000; 19: 325Google Scholar
- 37.Rodenhuis S, Botenbal M, Beex LVAM, et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin in operable breast cancer with 4 or more axillary lymph nodes [abstract]. Proc Am Soc Clin Oncol 2000; 19: 74Google Scholar
- 40.Peters W, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 1Google Scholar